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Thrombocytopenia–absent radius (TAR) syndrome is characterized by hypomegakaryocytic thrombocytopenia and bi-
lateral radial aplasia in the presence of both thumbs. Other frequent associations are congenital heart disease and a high
incidence of cow’s milk intolerance. Evidence for autosomal recessive inheritance comes from families with several affected
individuals born to unaffected parents, but several other observations argue for a more complex pattern of inheritance.
In this study, we describe a common interstitial microdeletion of 200 kb on chromosome 1q21.1 in all 30 investigated
patients with TAR syndrome, detected by microarray-based comparative genomic hybridization. Analysis of the parents
revealed that this deletion occurred de novo in 25% of affected individuals. Intriguingly, inheritance of the deletion
along the maternal line as well as the paternal line was observed. The absence of this deletion in a cohort of control
individuals argues for a specific role played by the microdeletion in the pathogenesis of TAR syndrome. We hypothesize
that TAR syndrome is associated with a deletion on chromosome 1q21.1 but that the phenotype develops only in the
presence of an additional as-yet-unknown modifier (mTAR).
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Thrombocytopenia–absent radius (TAR) syndrome (MIM
274000) is a clinically well-characterized malformation
syndrome. According to the diagnostic criteria defined by
J. Hall in 1969, typical clinical features are hypomega-
karyocytic thrombocytopenia and bilateral absence of the
radius in the presence of both thumbs.1 These character-
istic patterns differentiate TAR syndrome from other con-
ditions with involvement of the radius—that is, Holt-
Oram syndrome (MIM 142900), Roberts syndrome (MIM
268300), and Fanconi anemia (MIM 227650)—in which
the thumb is usually absent or severely hypoplastic. Ad-
ditional skeletal features associated with TAR syndrome
include shortening and, less commonly, aplasia of the
ulna and/or humerus. In the latter situation, the five-
fingered hand arises from the shoulder. The hands may
show limited extension of the fingers, radial deviation,
and hypoplasia of the carpal and phalangeal bones. The
lower limbs are frequently involved, but usually to a lesser
extent than are the upper limbs. Dislocation of the hips
and subluxation of the knees resulting in coxa vara are
common. Extraskeletal manifestations comprise cardiac
abnormalities, such as tetralogy of Fallot and atrial septal
defects, and abnormalities of the genitourinary tract.
Cow’s milk allergy or intolerance appears to be relatively
common among patients with TAR syndrome and may
provoke eosinophilia.2 Patients with TAR syndrome typi-
cally present with petechiae and severe bleeding during
the first years of life. Platelet counts are often !50 platelets/
nl (normal range 150–400 platelets/nl) due to impaired
presence or maturation of megakaryocytic progenitors in
the bone marrow.3,4 Although platelet counts ameliorate
over time, patients remain thrombocytopenic with con-
tinued risk of bleeding. In addition, young patients with
TAR syndrome have been reported to have leukemoid re-
actions with white blood counts exceeding 35,000 cells/
mm3. Similar to the thrombocytopenia, they are transient
in nature and not associated with true leukemia.5
The genetic basis of TAR syndrome remains unclear.
Different modes of inheritance—that is, autosomal reces-
sive, autosomal dominant, or autosomal dominant with
reduced penetrance—have been discussed in the litera-
ture.1,2,6 Generally, the pattern of inheritance is most con-
sistent with autosomal recessive inheritance.7 However,
there does not appear to be an increased incidence of con-
sanguinity in families with TAR syndrome, as would be
expected for a rare autosomal recessive disorder. Several
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Table 1. Clinical Description of Patients
with TAR Syndrome
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 1. Pedigrees of TAR-affected families. The legend is avail-
able in its entirety in the online edition of The American Journal
of Human Genetics.
Table 2. Primer Sequences for qPCR Analysis
Primer Name
Primer Sequence
(5′r3′) Amplicon Position
Forward Reverse Start Stop
1 Chr1-No3 TTGGGTAAGAACGGAGATGG CACCTTTCATCAAGGGAGGA 144014365 144014445
2 Chr1-No5 AATCTAGGTGGGGCTGTGTG CCTTTCTCATCCAGCAGCTC 144041972 144042069
3 NK GCTTCAATGTCTCCCGTGTTCT TGGCCGTAGATAATCTCATATGTTTG 144096959 144097039
4 NK2 TGAGTGGTCTTCGGGTGATAGA CCCATCCCACTGAAAACTGAA 144110432 144110519
5 hChr1-A CAGATGCTTGAAATGGAGTAAATGC TCCCTGAGATAGCAACAGTATCTGA 144128930 144129015
6 PIAS3-I9-10 CTTCCCACTGAGCATTGCAA GAGGTTAAGACTAGCAAGATCAAAAGATT 144294022 144294099
7 POLR3C I13-14 GGAAAATGGTAAAGGGTGGTG CATCTTCCCTAACCTGGGAGA 144305571 144305643
8 POLR3C I11-12 GTAACCAACCAAGGGCGTAA GTTTGCTTGGGGGTTCAGTA 144308167 144308260
9 ZNF364 I1-2 TCCTGAGTGTGATTGATTCTGGAT AAATTCGAAGTGCTGTACTTCACAA 144339188 144339268
10 hChr1-C (ZNF364 I2-3) TGGTATCCAGCAGTTCCTGTGA TGTCCCCATGAAATTTGCAA 144360856 144360946
11 hChr1-D (ZNF364 I4-5) GAGAAGAAACAGCCAGGGAAGTAC TGCTAAAACCAGGTAAGAGTCTTCAC 144387303 144387389
families have been reported with affected individuals
spread across 2 or even 3 generations,6 an unexpected find-
ing in nonconsanguineous pedigrees. In addition, parent-
to-child transmission has been reported.8 Several expla-
nations have been put forward to explain these unusual
observations. Hall et al.7 suggested that patients with TAR
syndrome may be genetic compounds. In this case, TAR
syndrome would follow a digenic inheritance similar to
the situation described for Bardet-Biedl syndrome.9 Also,
the possibility that Roberts syndrome and TAR syndrome
are allelic conditions has been discussed. However, Roberts
syndrome was shown to be caused by mutations in the
ESCO2 gene, the protein product of which is required for
the establishment of sister chromatid cohesion during S
phase,10 but ESCO2 mutations are not observed in TAR
syndrome.
Sequencing of candidate genes like HoxA10, HoxA11,
HoxD11, and c-mpl, the thrombopoietin receptor gene,
was performed, but no mutations were identified.11,12
Given the unclear inheritance and the frequently sporadic
nature of TAR syndrome, we searched for genomic aber-
rations in 30 patients with TAR syndrome and their fam-
ilies, using high-resolution microarray-based comparative
genomic hybridization (array CGH13,14). We identified a
common 200-kb microdeletion on the long arm of chro-
mosome 1 in all the affected and in 25 (32%) of the 78
unaffected family members. Our results indicate that TAR
syndrome is associated with a microdeletion on 1q21.1
that is necessary but not sufficient to cause the phenotype.
Material and Methods
Patients
We examined samples from 30 unrelated patients with TAR syn-
drome. All patients fulfill the diagnostic criteria for TAR syn-
drome: bilateral radial aplasia in the presence of both thumbs
and thrombocytopenia.
Patients were clinically assessed by at least one of us. Blood
samples were collected from the patients, their parents, and ad-
ditional family members if available. Informed consent was ob-
tained from all patients, their parents, and family members from
whom a blood sample was collected. One patient (patient 16),
described elsewhere, was suggested to have an overlapping phe-
notype of Roberts syndrome and TAR syndrome.15 Clinical data
are summarized in table 1. Pedigrees of all families are shown in
figure 1. The investigated patients with TAR syndrome originate
from different regions of the world, including Germany, the
United Kingdom, the United States, Lebanon, and India.
Cytogenetics and Array CGH
Karyotyping of GTG-banded chromosomes from lymphocytes at
450-band resolution was performed according to standard pro-
cedures. Four patients were analyzed by array CGH by use of a
submegabase-resolution whole-genome tiling path BAC array
consisting of the human 32K Re-Array set (DNA and clones kindly
provided by Pieter de Jong, BACPAC Resources Center17–19), the
1-Mb Sanger Clone set (clones kindly provided by Nigel Carter,
Wellcome Trust Sanger Institute20), and a set of 390 subtelomeric
clones (generated in the course of the European Union initiative
COSTB19: Molecular Cytogenetics of Solid Tumors). Array CGH
hybridization and analysis by CGHPRO was performed as de-
scribed elsewhere.21–23 Detailed protocols are also available at the
Max Planck Institute for Molecular Genetics: Molecular Cytoge-
netics Group Web site. Copy-number gains and losses were de-
termined by use of a conservative threshold of 0.3 and 0.3,
respectively. Aberrant signals including three or more neighbor-
ing BAC clones were considered genomic aberrations and were
further evaluated by FISH, unless they coincided with a published
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Table 3. Primer Sequences for Sequencing
Analysis
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 2. A, Adult patient (patient 1) with moderate upper-limb involvement. Note the radial deviation of both hands. B, Patient 9,
showing mild upper-limb involvement with slightly reduced lengths of the arms. C, Severe phenotype with phocomelia (patient 20).
D, Phocomelia in a severely affected patient (patient 8), and bowing of the long bones (E).
DNA copy-number variant as listed in the Database of Genomic
Variants (version June 2006).
FISH
BAC clones RP11-698N18 and RP11-258G05 (obtained from the
RZPD, Deutsches Resourcenzentrum fu¨r Genomforschung,Berlin,
Germany) were fluorescently labeled using nick translation and
were hybridized to metaphase spreads of the patient’s lympho-
cytes by use of standard procedures. BAC clones were labeled with
Spectrum Orange. Cep1 (Vysis) labeled with Spectrum Green was
used as a control probe. Chromosomes were counterstained with
4′,6-diamidino-2-phenylindole. Image analysis was performed us-
ing the ISIS analysis system (Metasystems).
Quantitative Real-Time PCR (qPCR)
To evaluate genomic DNA for the microdeletion 1q21.1 and to
map the breakpoint at a higher resolution, we developed a qPCR
test, using a set of 11 primer pairs located within the deletion.
Genomic DNA was extracted from blood or buccal smears by use
of standard methods. qPCR was performed in a total volume of
24 ml in each well containing 12 ml of SYBR Green PCR Master
Mix (Applied Biosystems), 10 ml of genomic DNA (1 ng/ml), and
2 ml of primers (0.2 mmol each). Samples were run in triplicate in
separate tubes to permit the quantification of the target sequences
normalized to Albumin. PCR conditions were as follows: initial
denaturation step at 95C followed by 40 cycles at 95C for 15 s
and 60C for 1 min. By use of calibrator samples of normal control
DNA, the gene copy number was estimated on the basis of the
comparative DDCt method. In addition, we performed a sex de-
termination for the individuals, calculating the Factor VIII exon
3 relative to our endogenous control Albumin, to assure its reli-
ability. Primer sequences are given in table 2.
Candidate-Gene Sequencing
To test for possible point mutations or small deletions in genes
within the deleted region, we sequenced the coding region of the
genes HFE2, LIX1L, PIAS3, ANKRD35, ITGA10, RBM8A, PEX11B,
POLR3GL, TXNIP, and GNRR2 on the nondeleted allele in three
patients with TAR syndrome. Primer sequences are given in ta-
ble 3.
Results
Clinical Features of Patients with TAR Syndrome
The patients with TAR syndrome examined in this study
included 19 females and 11 males, with ages ranging from
6 months to 45 years. The study includes one case of ver-
tical transmission (an affected mother had an affected fe-
tus; patients 29 and 30). Six probands have unaffected
siblings, and, in one family, two brothers are affected (pa-
tients 25 and 26) (for pedigrees, see fig. 1).
All patients studied here had a documented thrombo-
cytopenia defined as a platelet count !150 platelets/nl and
bilateral radial aplasia (for clinical details, see table 1). We
observed a considerable clinical variability with some in-
dividuals presenting with minor additional upper-limbab-
normalities, whereas others showed severe phocomelia
(fig. 2). Lower-limb involvement, including hip dysplasia,
genua vara, and bowing of long bones, was present in 16
patients, and short stature (height 3rd percentile) was
seen in 9 patients. Cardiac anomalies, such as ventricular
septal defect, occurred in three patients, and genitourinary
anomalies, including horseshoe kidney, hypoplasia of the
uterus and vagina, and renal pelvis dilation, were observed
in four patients. Eight patients were described as having
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Figure 3. A, Array CGH profile of chromosome 1 (patient 1). Note
the microdeletion in 1q21.1. B–E, Confirmation of the microde-
letion by FISH. B, Deletion of RP11-698N18 (labeled with Spectrum
green) and two normal signals of control probe CEP1 (labeled with
Spectrum orange) (patient 4). C, Partial deletion of RP11-258G05
(labeled with Spectrum green) and two normal signals of control
probe CEP1 (labeled with Spectrum orange) (patient 4). D, Deletion
of RP11-258G05 (labeled with Spectrum green) and two normal
signals of control probe RP11-5P4 located in chromosomal band
1p31.3 (labeled with Spectrum orange) (patient 7). E, Two normal
signals of RP11-258G05 (labeled with Spectrum green) and of con-
trol probe RP11-5P4 (labeled with Spectrum orange) (patient 20).
cow’s milk intolerance and increased susceptibility to gas-
troenteritis. Two patients had sensorineural hearing loss
and one had a cleft lip and palate.
Microdeletion Associated with TAR Syndrome
No cytogenetic abnormalities were detected by standard
karyotyping of GTG-banded metaphase chromosomes
from patients’ lymphocytes. To investigate the genomic
DNA of patients with TAR syndrome for submicroscopic
aberrations, we performed array CGH analysis, using a
whole-genome tiling path BAC array.18,19,23,24 Initially, we
analyzed four patients with TAR syndrome and detected
an interstitial deletion on chromosome 1q21.1 (fig. 3A).
Array CGH data were submitted to the Gene Expression
Omnibus (GEO) database (provisional series number
GSE5781). According to the array CGH data, the two
breakpoints were located between BAC clones RP11-
458D21 and RP11-698N18 (proximal breakpoint) and
RP11-258G05 and RP11-399E17 (distal breakpoint). The
deletion was determined to be localized between positions
144.1 Mb and 144.6 Mb on chromosome 1 (Ensembl, v39,
June 2006). The deletion encompasses 19 annotated genes
and transcripts (fig. 4). The flanking BACs RP11-458D21
(proximal to deletion) and RP13-553C06 (distal to dele-
tion) showed normal log2 ratios. Both breakpoints were
found to be enriched for low-copy repeats, and, according
to the Segmental Duplication Database, the deleted seg-
ment is flanked by duplication clusters with 93%–99%
sequence identity. The proximal breakpoint coincided
with published DNA copy-number polymorphisms.25 The
detected deletion was not present in 700 control samples
with different phenotypes examined by one of us (R.U.)
using the same array platform. Furthermore, a similar de-
letion is not described in the Database of Genomic Vari-
ants (version June 2006).
To confirm the array CGH data and to examine addi-
tional patients with TAR syndrome, we performed FISH
analysis, using two BAC clones mapping to the deleted
region at 1q21.1 (fig. 4). The FISH results confirmed an
interstitial deletion of ∼500 kb on chromosome 1q21.1 in
all investigated patients with TAR syndrome. A single sig-
nal was detected on index patients’ metaphases with BAC
clone RP11-698N18 (located at the proximal deletion
breakpoint) (fig. 3B), whereas the more distal BAC clone
RP11-258G05 located at the distal deletion breakpoint
showed two signals. However, one signal was always
weaker, indicating that BAC clone RP11-258G05 spans the
distal breakpoint (fig. 3C). Thus, the FISH results con-
firmed an interstitial deletion of ∼500 kb on chromosome
1q21.1. In two families, deviating FISH signals were de-
tected: patient 7 showed complete deletion of both BAC
clones on one chromosome 1 (fig. 3D), whereas deletion
of RP11-698N18 and two signals of equal intensity for the
distal probe RP11-258G05 were observed in patient 20 (fig.
3E). These results demonstrate that the distal breakpoint
is variable and that the common deletion is smaller in
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Figure 4. Schematic representation of the 1q21.1 genomic region. Positions of the genes, BAC clones, and qPCR amplicons are
indicated. The extent of the microdeletions detected in patients with TAR syndrome are indicated by bars. The number of patients with
the respective deletion is given on the right side.
patient 20 than in patient 7. Despite carrying the smallest
deletion, patient 20 presents with a severe phenotype, in-
cluding phocomelia and lower-limb involvement, indi-
cating that the critical region for TAR syndrome is located
within the region covered by the more proximally located
BACs RP11-698N18 and RP11-293J20 (fig. 4). To further
investigate the telomeric breakpoint, we performed a qPCR
analysis of the deleted region in patient 20, which nar-
rowed the breakpoint to a 2.5-kb region within the POLR3C
gene between positions 144,305,643 and 144,308,167 bp
on chromosome 1 (fig. 5B). In total, 20 patients with TAR
syndrome and 59 unaffected family members were ex-
amined by FISH. Since metaphase preparations were not
available for 31 individuals (10 patients with TAR syn-
drome and 21 unaffected relatives), we established a qPCR
assay to analyze the 1q21.1 region. The deletion was de-
tected by qPCR in an additional 10 of 10 patients with
TAR syndrome and 6 of 21 relatives (fig. 5A). To rule out
point mutations on the other nondeleted allele, we ana-
lyzed the coding sequences of 10 genes (HFE2, LIX1L,
PIAS3, ANKRD35, ITGA10, RBM8A, PEX11B, POLR3GL,
TXNIP, and GNRR2) located within the deletion in three
patients with TAR syndrome. We detected no mutations
but several polymorphisms that were also found in a con-
trol population and were not present in all the patients
with TAR syndrome examined.
Inheritance of the Deletion
Taken together, the FISH and qPCR results revealed that
the microdeletion was inherited from one of the unaf-
fected parents in the majority of patients. We observed
maternal inheritance for 12 patients, paternal inheritance
for 5 patients, and de novo occurrence for 5 patients. In
the remaining patients, the pattern of inheritance could
not be investigated, because DNA samples from the par-
ents were not available for examination. The deletion can
be traced back to the generation of the grandparents in
four families (families 2, 4, 7, and 8). In two instances,
the microdeletion occurred de novo in one of the parents
(one male and one female, in families 5 and 9, respec-
tively). In several families, we were able to demonstrate
that unaffected siblings and relatives had inherited the
deletion. In the family with vertical transmission, the de-
letion was demonstrated in both the affected mother and
the affected fetus.
Discussion
Here, we describe a common microdeletion in patients
with TAR syndrome that encompasses 200 kb and 11 genes
on chromosome 1q21.1. In 25% of the investigated pa-
tients, the deletion occurred de novo. In the other 75%,
however, the deletion was inherited from either the un-
affected mother or the unaffected father. The deletion is
likely to be causative, because deletions and duplications
in this genomic region were not observed in 700 other
individuals and are also not described as DNA copy-num-
ber variants in the Database of Genomic Variants. Several
genes with known functions are located within the deleted
region (fig. 4). PIAS3 is the most conspicuous candidate
among the genes within the deleted region. It acts as a
negative regulator of activated, phosphorylated Stat3, a
transcription factor involved in hematopoietic growth-
factor signaling.26 Binding of thrombopoietin to its recep-
tor, c-Mpl, results in activation of Jak2 kinase and distinct
Stat family members, among which Stat3 is the most
prominent.27,28 Nevertheless, monoallelic expression of a
negative regulator should result in stabilization of the ac-
tivated Jak2/Stat3 pathway in response to thrombopoie-
tin, which we did not observe in patients with TAR syn-
drome.29 A simple model including PIAS3 hemizygosity
can therefore be excluded, although more-complex mod-
els including the PIAS3-binding protein Gfi-1 are feasi-
ble.30 Lix1L is a second candidate gene, harboring com-
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Figure 5. A, Copy-number analysis by qPCR. The mean values for relative quantification (RQ) were exported from the 7500 SDS software.
For all three groups (affected with deletion, nonaffected with deletion, and nonaffected without deletion) mean values and SDs (error
bars) for each target primer relative to Albumin as a two-copy reference gene were calculated. Results were calibrated to the mean
value determined for a healthy female control. A, C, and D refer to primers shown in table 2 (hChr1-A, hChr1-C, and hChr1-D, respectively).
B, For determination of the distal breakpoint, the two carriers of the small deletion (patient 20 and nonaffected mother) were compared
with the same control as in panel A and one nonaffected male deletion carrier. The breakpoint of the smaller deletion maps to the
region between introns 11–12 and introns 13–14 of POLR3C (∼2.5 kb). Two target sequences located proximal to the deletion (Chr1-
No3 and Chr1-No5) displayed normal copy numbers in all samples. The error bars indicate the 95% CI as calculated by the 7500 SDS
software. F8 p factor VIII gene.
putational sequence homology to Lix1, a gene reported to
be transiently expressed during chick hind-limb devel-
opment.31 None of the other genes within the deleted in-
terval has a known function in limb development or
hematopoiesis.
Our finding that carriers of the microdeletion (i.e., clin-
ically inconspicuous parents and grandparents) are not
affected implies that haploinsufficiency of the deleted re-
gion is not sufficient to cause TAR syndrome or, for that
matter, any obvious signs or symptoms in the carrier. The
possibility of a deletion on one allele and a point mutation
or small deletion on the other allele cannot be excluded.
However, the absence of any significant change in the
genes located within the deletion on the nondeleted allele
argues against this possibility. Furthermore, the occur-
rence of vertical transmission—one case described here
and additional cases in the literature8—argues in favor of
other models of inheritance. Thus, TAR syndrome does
not appear to follow a standard autosomal dominant or
autosomal recessive pattern of inheritance. The possibility
of genomic imprinting as an underlying mechanism can
be excluded, since we detected maternal (12/22) as well
as paternal (5/22) transmission of the deletion among the
unaffected carrier parents. In addition, reports of maternal
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as well as paternal uniparental disomy of chromosome 1
describe no severe phenotypes, no malformations, and no
hematopoietic abnormalities in affected individuals.32–34
Another explanation for the unusual pattern of inher-
itance observed is random monoallelic expression caused
by methylation of one allele, as described elsewhere for
association with Paris-Trousseau/Jacobsen thrombocyto-
penia.35 To a certain degree, this mechanism can be re-
garded as an autosomal analogue to X inactivation re-
sulting in a mosaic state. Mutations in one allele further
reduce the gene dosage to a disease-causing level. Since
the inactivation is random, the differences between af-
fected and unaffected carriers of the mutation can be ex-
plained only by stochastic effects or by alterations in a
second gene that controls the methylation in this region.
The idea of multiple allelism in TAR syndrome was
raised by Hall.1 Autosomal recessive inheritance on the
basis of two nonidentical mutant alleles was discussed as
one option. Digenic inheritance must also be considered,
and it implies that mutations (or, in this case, at least one
microdeletion) in each of two unlinked loci have to be
present in an affected individual, and only this combi-
nation of the two genetic hits—that is, double heterozy-
gosity—causes the disease phenotype or possibly affects
the severity of the phenotype. Carriers with alterations at
only one of the two loci do not show the disease phe-
notype. Recently described examples for digenic inheri-
tance in human disease are retinitis pigmentosa36 and Bar-
det-Biedl syndrome.37 Two distinct categories have been
specified38: (1) two mutations act in a synergistic fashion
with multiplicative effect on the phenotype or (2) both
mutations have additive effects, with the second muta-
tion acting as a modifier to increase the severity of the
phenotype.
In TAR syndrome, this would involve two genetic
changes: one rare mutation (the microdeletion) and one
relatively frequent change or polymorphism that func-
tions in this situation as a modifier of the other. The mod-
ifier theory has been studied in detail in the context of
the dactylaplasia mutation (Dac) in mice, the murine
equivalent to human ectrodactyly. Affected patients and
Dac mice have hypoplasia of the middle part of the distal
limbs, a phenotype that is extremely variable, ranging
from syndactyly to monodactyly. Because Dac mice ex-
hibit the ectrodactyly phenotype only on certain genetic
backgrounds, it was postulated that the manifestation of
the mutant gene Dac is controlled by another locus, which
was termed “mdac.”39 The mutation is expressed as an au-
tosomal semidominant trait only if the mdac allele is ho-
mozygous. This hypothesis was verified by the identifi-
cation of the Dac mutation40 and the mapping of mdac to
mouse chromosome 13.41
A similar situation may exist in TAR syndrome. The ob-
served microdeletion is the prerequisite for the pheno-
type. This deletion mutation is rare and predisposes an
individual to TAR syndrome, but the presence of an ad-
ditional modifier is required to elicit the phenotype. The
modifier (mTAR) is likely to be a relatively common poly-
morphism, as indicated by the ratio of affected to unaf-
fected deletion carriers. mTAR could be inherited in a
dominant or recessive fashion, with both possibilities re-
sulting in the observed recurrence risk of ∼25%. Sporadic
cases arise if the deletion occurs de novo and if the mod-
ifier mTAR is inherited from one parent (dominant) or
both parents (recessive). If one of the parents carries the
deletion, it will be transmitted to 50% of the children, but
only those who have also inherited mTAR will develop
TAR syndrome. Likewise, a parent-to-child transmission is
possible if the child inherits the deletion from the affected
parent along with mTAR from either or both parents. Al-
though one would expect TAR syndrome in 25% of the
offspring in the case of a dominant modifier, parent-to-
child transmission of TAR syndrome is rare. Thus, a model
with one or more recessively acting modifiers appears
more likely. We therefore propose that TAR syndrome be
considered not a single-gene disease but a complex trait
requiring at least two unlinked alleles—one rare, the other
frequent—to manifest the phenotype.
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